
A Safer Approach to HDAC Inhibition: Chidamide (Epidaza) for Lymphoma and Breast Cancer
In the field of oncology, relapsed or refractory peripheral T-cell lymphoma (PTCL) and endocrine therapy resistance in HR-positive advanced breast cancer remain two major clinical





















